HansaBioMed Life Sciences

The NAP4DIVE Project

Ongoing

NAP4DIVE aims to reduce animal use in Central Nervous System drug development by up to 95% while saving 30 % of costs.

Project Information

Non-animal platform for nanoparticle-based delivery across the blood-brain barrier interface with vehicle evolution.

Our Role

HansaBioMed Life Sciences is involved in the production and upscaling of nanoparticle manufacturing and quality control.

Partners

HansaBioMed Life Sciences, Åbo Akademi University, Finnadvance, AstraZeneca plc, The University of Gothenburg, Chalmers University of Technology, The Microfluidics Innovation Center, Delft University of Technology, Betthera s.r.o., AMIRES S.R.O. , Eindhoven University of Technology

Back to All Projects

Other Projects

All Projects